|
|
|
REFERENCES
VOLUME 1 ISSUE 4 CASE JJ
- National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III). Executive Summary. NIH Publication 01-3670, May 2001. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/.
- American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2003;26(suppl 1):S94-S98.
- Trevisan R, Viberti G. Pathophysiology of Diabetic Nephropathy. In: LeRoith D, Taylor SI, Olefsty JM, eds. Diabetes Mellitus. A Fundamental and Clinical Text. Second ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:898-909.
- Kussman MJ, Gildstein HH, Gleason RE. The clinical course of diabetic nephropathy. JAMA. 1976;236:1861-1863.
- Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med. 2003;254:45-66.
- Mattock MB, Morrish NJ, Viberti G, et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41(6):736-741.
- Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676-1685.
- Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H. Albuminuria and poor metabolic control predict mortality in NIDDM. Diabetes. 1995;44:1303-1309.
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
- Rosner MH, Okusa MD. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Arch Intern Med. 2003;163:1025-1029.
- Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care. 2003;26:2268-2274.
- Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63:1874-1880.
- American Diabetes Association. Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care 2003 26:S33-S50.
- Dagogo-Jack S. Diabetes mellitus and related disorders. In: Ahya S, Flood K, eds. The Washington Manual of Medical Therapeutics. 30th ed. New York, NY: Lippincott; 2001:455-472.
|
|
The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Return to Thomas Jefferson University Home Page
|
